RU2010103455A - Способ уменьшения симптомов употребления алкоголя - Google Patents

Способ уменьшения симптомов употребления алкоголя Download PDF

Info

Publication number
RU2010103455A
RU2010103455A RU2010103455/15A RU2010103455A RU2010103455A RU 2010103455 A RU2010103455 A RU 2010103455A RU 2010103455/15 A RU2010103455/15 A RU 2010103455/15A RU 2010103455 A RU2010103455 A RU 2010103455A RU 2010103455 A RU2010103455 A RU 2010103455A
Authority
RU
Russia
Prior art keywords
composition
composition according
metadoxine
individual
specified
Prior art date
Application number
RU2010103455/15A
Other languages
English (en)
Other versions
RU2526157C2 (ru
Inventor
Гур МЕГИДДО (IL)
Гур МЕГИДДО
Далия МЕГИДДО (IL)
Далия Мегиддо
Рина ЯМИН (IL)
Рина Ямин
Ярон ИЛАН (IL)
Ярон Илан
Шимон АМСЕЛЕМ (IL)
Шимон Амселем
Original Assignee
Алкобра Лтд. (Il)
Алкобра Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL184389A external-priority patent/IL184389A0/en
Application filed by Алкобра Лтд. (Il), Алкобра Лтд. filed Critical Алкобра Лтд. (Il)
Publication of RU2010103455A publication Critical patent/RU2010103455A/ru
Application granted granted Critical
Publication of RU2526157C2 publication Critical patent/RU2526157C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

1. Композиция, содержащая метадоксин, для применения в предупреждении алкогольной интоксикации у нуждающегося в этом индивидуума, где указанный индивидуум не достиг интоксикации. ! 2. Композиция по п.1, где указанный индивидуум участвует или будет участвовать в социальном распитии алкоголя, серийном распитии алкоголя или кутежном распитии алкоголя. ! 3. Композиция по п.1 или 2, где указанная композиция вводится в одной лекарственной форме или ее части. ! 4. Композиция по п.1 или 2, где указанный метод введения представляет собой пероральное, сублингвальное, буккальное, интраназальное, трансдермальное, чрезслизистое, ректальное или подкожное введение. ! 5. Композиция по п.1, где указанный индивидуум не страдает острым алкоголизмом. !6. Композиция, содержащая метадоксин, включенный в состав для длительного или контролируемого высвобождения после введения индивидууму. ! 7. Композиция, содержащая метадоксин, где часть метадоксина включена в состав для длительного высвобождения, и часть метадоксина включена в состав для немедленного высвобождения после введения индивидууму. ! 8. Композиция по п.6, где пропорция метадоксина длительного высвобождения относительно метадоксина немедленного высвобождения находится в диапазоне от 1 к 99 до 99 к 1, в целых значениях. ! 9. Композиция по любому из пп.6-8, выбранная из фармацевтической композиции, пищевой добавки, пищевого продукта и напитка. ! 10. Композиция по любому из пп.6-8, где указанный метадоксин представляет собой физиологически совместимое производное. ! 11. Композиция по любому из пп.6-8, где указанная композиция включена в препаративную форму для высвобождения не менее чем 50% общ�

Claims (18)

1. Композиция, содержащая метадоксин, для применения в предупреждении алкогольной интоксикации у нуждающегося в этом индивидуума, где указанный индивидуум не достиг интоксикации.
2. Композиция по п.1, где указанный индивидуум участвует или будет участвовать в социальном распитии алкоголя, серийном распитии алкоголя или кутежном распитии алкоголя.
3. Композиция по п.1 или 2, где указанная композиция вводится в одной лекарственной форме или ее части.
4. Композиция по п.1 или 2, где указанный метод введения представляет собой пероральное, сублингвальное, буккальное, интраназальное, трансдермальное, чрезслизистое, ректальное или подкожное введение.
5. Композиция по п.1, где указанный индивидуум не страдает острым алкоголизмом.
6. Композиция, содержащая метадоксин, включенный в состав для длительного или контролируемого высвобождения после введения индивидууму.
7. Композиция, содержащая метадоксин, где часть метадоксина включена в состав для длительного высвобождения, и часть метадоксина включена в состав для немедленного высвобождения после введения индивидууму.
8. Композиция по п.6, где пропорция метадоксина длительного высвобождения относительно метадоксина немедленного высвобождения находится в диапазоне от 1 к 99 до 99 к 1, в целых значениях.
9. Композиция по любому из пп.6-8, выбранная из фармацевтической композиции, пищевой добавки, пищевого продукта и напитка.
10. Композиция по любому из пп.6-8, где указанный метадоксин представляет собой физиологически совместимое производное.
11. Композиция по любому из пп.6-8, где указанная композиция включена в препаративную форму для высвобождения не менее чем 50% общего количества метадоксина в пределах 8 ч, предпочтительно, в пределах 6 ч.
12. Композиция по любому из пп.6-8, где указанная композиция имеет tmax метадоксина в крови более чем примерно 1 ч.
13. Композиция по любому из пп.6-8, где указанная композиция составлена для доставки до 3000 мг метадоксина при введении одной дозы или ее части.
14. Композиция по любому из пп.6-8, где указанная композиция, кроме того, содержит по меньшей мере один из полимерного материала, усилителя абсорбции и приемлемого эксципиента.
15. Композиция по любому из пп.6-8, где указанная композиция содержит или состоит по существу из формулы 1, формулы 2 или формулы 3.
16. Композиция метадоксина по любому из пп.6-8 для применения для увеличения среднего tmax метадоксина в крови нуждающегося в этом индивидуума.
17. Композиция по п.16, где указанная композиция имеет tmax метадоксина в крови примерно вдвое больше, чем у композиции немедленного высвобождения.
18. Устройство для доставки лекарственного средства, содержащее композицию метадоксина по любому из пп.6-17.
RU2010103455/15A 2007-07-03 2008-07-03 Способ уменьшения симптомов употребления алкоголя RU2526157C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL184389A IL184389A0 (en) 2007-07-03 2007-07-03 Use of metadoxine in relief alcohol intoxication
IL184389 2007-07-03
IL187159A IL187159A0 (en) 2007-07-03 2007-11-05 Use of metadoxine in relief of alcohol intoxication
IL187159 2007-11-05
PCT/IL2008/000917 WO2009004629A2 (en) 2007-07-03 2008-07-03 A method for decreasing symptoms of alcohol consumption

Publications (2)

Publication Number Publication Date
RU2010103455A true RU2010103455A (ru) 2011-08-10
RU2526157C2 RU2526157C2 (ru) 2014-08-20

Family

ID=40226624

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010103455/15A RU2526157C2 (ru) 2007-07-03 2008-07-03 Способ уменьшения симптомов употребления алкоголя

Country Status (20)

Country Link
US (3) US20100256198A1 (ru)
EP (2) EP2716288A1 (ru)
JP (2) JP2010531872A (ru)
KR (3) KR20150046394A (ru)
CN (2) CN101795687A (ru)
AU (1) AU2008272420B2 (ru)
BR (1) BRPI0814617A2 (ru)
CA (1) CA2691973C (ru)
CY (1) CY1116931T1 (ru)
DK (1) DK2173345T3 (ru)
ES (1) ES2552717T3 (ru)
HR (1) HRP20151202T1 (ru)
HU (1) HUE028078T2 (ru)
IL (2) IL187159A0 (ru)
MX (1) MX2010000266A (ru)
PL (1) PL2173345T3 (ru)
PT (1) PT2173345E (ru)
RU (1) RU2526157C2 (ru)
SI (1) SI2173345T1 (ru)
WO (1) WO2009004629A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
KR101068686B1 (ko) * 2009-02-17 2011-09-29 서울대학교산학협력단 메타독신을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물
EP2445498A1 (en) * 2009-06-25 2012-05-02 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
CN102784101A (zh) * 2012-08-06 2012-11-21 济南维尔康生化制药有限公司 一种美他多辛注射剂及其制备方法
BR112015006642B1 (pt) * 2012-09-26 2022-08-02 Eurodrug Laboratories B.V Composição farmacêutica de liberação prolongada compreendendo metadoxina e prednisona
CN103340826B (zh) * 2013-07-05 2015-09-09 浙江震元制药有限公司 美他多辛注射用组合物及其制备方法
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
TW201605443A (zh) 2013-09-09 2016-02-16 亞克柏拉有限公司 治療ｘ染色體脆折症及相關病症的方法
KR101591429B1 (ko) * 2014-04-07 2016-02-04 강릉원주대학교산학협력단 신규 숙취개선 및 간보호용 조성물
CN103989625B (zh) * 2014-05-15 2016-03-02 金伟华 一种由美他多辛作为药用成分制备的栓剂及其制备方法
CN103976970A (zh) * 2014-06-06 2014-08-13 程奉平 美他多辛缓释片的制备方法
IL266674B2 (en) 2016-11-18 2024-09-01 Opiant Pharmaceuticals Inc Compositions, devices and methods of using intranasal nalmefene and dodecyl maltoside for treatment of opioid overdose
WO2019028451A1 (en) 2017-08-04 2019-02-07 Global Battery Solutions Llc SYSTEM AND METHOD FOR MONITORING BATTERIES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1286161A (en) 1970-01-21 1972-08-23 Soc D Etudes Prod Chimique Pyridoxine mono-esters
FR2172906A1 (en) 1972-02-25 1973-10-05 Fabre Sa Pierre Salts of 3-pyridyl methanol derivs - vasodilators
IT1131855B (it) * 1980-06-30 1986-06-25 Baldacci Lab Spa Procedimento per la preparazione di pirrolidon carbossilato di piridossina
IT1131856B (it) * 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
JPH02138128A (ja) * 1988-11-19 1990-05-28 Eiji Amaya 血中アルコール濃度降下薬
IT1244507B (it) 1991-04-11 1994-07-15 Sigma Tau Ind Farmaceuti Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
IT1263957B (it) * 1993-02-23 1996-09-05 Impiego terapeutico del pirrolidon carbossilato di piridossina
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5714531A (en) * 1996-01-22 1998-02-03 Japan Polychem Corporation Propylene resin extruded articles
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
ES2220789T3 (es) * 2000-10-30 2004-12-16 Lupin Limited Composicion de cefuroxima axetilo de liberacion lenta que se desintegra rapidamente.
US20020192303A1 (en) 2001-06-01 2002-12-19 Stefan Arver Treatment of side effects associated with alcohol consumption
WO2003003981A2 (en) 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US6541043B2 (en) * 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6913769B2 (en) 2003-02-18 2005-07-05 Brian Douglas Oslick Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption
CN1212842C (zh) * 2003-08-20 2005-08-03 杭州容立医药科技有限公司 美他多辛咀嚼片及其制备方法
ES2235626B1 (es) * 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US20050271739A1 (en) 2004-06-08 2005-12-08 Wang Xiang H Methods and compositions for accelerating alcohol metabolism
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
JP2006022056A (ja) * 2004-07-08 2006-01-26 I M B Kk 酒酔い防止剤
CN1301108C (zh) * 2004-10-15 2007-02-21 山东齐都药业有限公司 美他多辛分散片及其制备方法
WO2007038112A2 (en) * 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Combination of rosiglitazone and donepezil for improvement of cognitive function
US20070248696A1 (en) * 2006-04-25 2007-10-25 Mind Sports Nutrition Inc. Composition and method for enhancing neuromuscular facilitation and cognitive functions
KR100877600B1 (ko) * 2006-11-30 2009-01-08 재단법인서울대학교산학협력재단 메타독신 및 마늘유를 유효성분으로 함유하는 알코올성지방간 및 지방간성 간염의 예방 및 치료용 약학 조성물
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2445498A1 (en) * 2009-06-25 2012-05-02 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition

Also Published As

Publication number Publication date
PT2173345E (pt) 2015-11-19
US20120277270A1 (en) 2012-11-01
US9808446B2 (en) 2017-11-07
IL204528A0 (en) 2011-07-31
HRP20151202T1 (hr) 2015-12-04
US20150209338A1 (en) 2015-07-30
IL187159A0 (en) 2009-02-11
ES2552717T3 (es) 2015-12-01
EP2173345B1 (en) 2015-08-19
CY1116931T1 (el) 2017-04-05
SI2173345T1 (sl) 2015-12-31
US8476304B2 (en) 2013-07-02
HUE028078T2 (en) 2016-11-28
DK2173345T3 (en) 2015-11-23
JP2010531872A (ja) 2010-09-30
KR20100045457A (ko) 2010-05-03
CA2691973C (en) 2016-06-28
AU2008272420A1 (en) 2009-01-08
EP2173345A4 (en) 2010-09-29
CN106890130A (zh) 2017-06-27
PL2173345T3 (pl) 2016-01-29
CN101795687A (zh) 2010-08-04
KR20160054632A (ko) 2016-05-16
IL204528A (en) 2016-09-29
WO2009004629A2 (en) 2009-01-08
KR20150046394A (ko) 2015-04-29
MX2010000266A (es) 2010-05-03
EP2173345A2 (en) 2010-04-14
WO2009004629A3 (en) 2010-03-04
EP2716288A1 (en) 2014-04-09
CA2691973A1 (en) 2009-01-08
US20100256198A1 (en) 2010-10-07
JP2014058542A (ja) 2014-04-03
AU2008272420B2 (en) 2014-08-14
JP5661900B2 (ja) 2015-01-28
RU2526157C2 (ru) 2014-08-20
BRPI0814617A2 (pt) 2014-09-30

Similar Documents

Publication Publication Date Title
RU2010103455A (ru) Способ уменьшения симптомов употребления алкоголя
ES2314371T3 (es) Formas de administracion aromaticas, de larga duraccion para la liberacion prolongada de sustancias activas en la boca.
WO2005039499A3 (en) Rapidly disintegrating film
RU2012108632A (ru) Сублингвальные и буккальные пленочные композиции
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
PL372290A1 (en) Pharmaceutical dosage form for mucosal delivery
JP2007238598A5 (ru)
CN1927160A (zh) 漱口液及制备方法
CA2553890A1 (en) Pharmaceutical compositions comprising midazolam in a high concentration
JP2011500781A5 (ru)
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
CN105232781A (zh) 一种用于祛除口腔异味的喷雾剂及其制备方法
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
CA3151070A1 (en) Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids
US20110274728A1 (en) Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort
CN1883461A (zh) 口腔粘膜药物缓释贴片
CN101278948A (zh) 一种生物型药膜及其制备方法
JP5118863B2 (ja) 催眠用医薬組成物
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
JP2009539916A5 (ru)
CN109431976A (zh) 一种抗口腔溃疡的药物及其用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170704